drugset / Trial / NCT01932528
An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Males
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the metabolism and routes and extent of elimination of telotristat etiprate and its primary metabolite LX1033.
Timeline
- Start
- 2013-08
- Primary completion
- 2013-09
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 500 mg [14C]-LX1606 | Unknown | 3.32 mbq | Oral |
| Subject | 500 mg [14C]-LX1606 | Unknown | 500 mg | Oral |